Clinical overview
Recognise immune-mediated toxicity in any organ, grade severity, exclude infection and begin guideline-based immunosuppression when required.
Why this matters
This topic can materially affect diagnosis, treatment safety, organ function and long-term outcome. Interpretation should integrate severity, trajectory, comorbidity, medicines and the patient’s goals rather than relying on one result or score.
Initial assessment
Define tissue diagnosis, stage, molecular or receptor profile, performance status, frailty, organ function, treatment history, symptoms and patient goals. Identify oncological emergencies before routine staging.
Diagnostic strategy
Use high-quality pathology, disease-appropriate imaging and validated biomarkers. Ensure adequate material for molecular testing and review discordant findings through the multidisciplinary team.
Management principles
Match treatment intent and modality to tumour biology, stage, fitness and preference. Integrate surgery, radiotherapy, systemic treatment, supportive care, fertility, rehabilitation and follow-up.
Monitoring and treatment safety
Define baseline measurements, treatment targets, adverse-effect surveillance and the interval for review. Reassess diagnosis, adherence, interactions, organ function and treatment burden when the expected response is not achieved.
Special populations
Pregnancy, childhood, older age, frailty, kidney or liver dysfunction and immunosuppression may change diagnostic performance, medicine selection, dose and escalation thresholds. Use population-specific guidance and specialist advice.
Clinical pearls
- Trend and clinical trajectory are often more informative than a single measurement.
- Obtain definitive tissue, microbiology or fluid evidence when it will alter management.
- Document why a score, threshold or guideline applies to this patient.
Common mistakes
- Using screening or classification criteria as a stand-alone diagnosis.
- Failing to review medicines, interactions and organ function.
- Continuing ineffective treatment without reassessing the diagnosis or source.
- Delaying supportive, rehabilitative or palliative care until late in the pathway.
Escalation triggers
Escalate urgently for neutropenic sepsis, spinal-cord compression, tumour lysis, severe hypercalcaemia, superior vena cava obstruction, raised intracranial pressure or uncontrolled treatment toxicity, or whenever ward-level monitoring, diagnostic access or treatment capability is insufficient.
Related MediCalc clinical tools
Related Clinical References
Frequently asked questions
Can this reference replace a local specialist pathway?
No. Use current local prescribing, diagnostic, antimicrobial, transfusion, rheumatology or oncology protocols as applicable.
When should the diagnosis be reconsidered?
Reconsider it when the clinical course, repeat testing or treatment response is inconsistent with the working diagnosis.
Key practice points
- Recognise emergencies first.
- Obtain high-quality diagnostic evidence.
- Use specialist treatment safely.
- Reassess response and toxicity.
- Integrate prevention, rehabilitation and supportive care.